The 100th Registry Participant
By Rhonda Rowland

I’m study participant number 30 in the Wilson Disease (WD) Patient Registry. That’s not exciting.
However, if you’re participant number 100, you represent a milestone. And, that is exciting. Especially for those who’ve put in countless hours and tremendous effort to recruit patients, test them and analyze the data they’ve gathered, in order to glean new insights into a disease. The new findings are then published so they can be shared with other medical professionals, making it easier to spot new patients and give them the best possible treatment.

Michael L. Schilsky, MD Chair
Yale Medical Center
New Haven, Connecticut
The Wilson Disease Registry
Established in 2017 by Dr. Michael Schilsky at Yale University, the Wilson Disease Registry (WDR) is a global, long-term observational study sponsored by the Wilson Disease Association. Its mission is to enhance the understanding, diagnosis, treatment, and monitoring of individuals living with Wilson disease (WD).
What Is a Patient Registry?
A patient registry is a tool used to collect information about people who have a specific disease or condition. This information—such as symptoms, treatments, and outcomes—helps researchers and doctors better understand the disease over time.
For rare diseases like Wilson disease, patient registries are especially important. Because so few people are affected, it’s hard to gather enough data in one place. Registries solve this by bringing together information from patients around the world.
This shared data helps scientists ask the right questions, design better studies, and find people who may want to take part in future clinical trials. In short, patient registries are a vital part of improving care, discovering new treatments, and giving patients a stronger voice in research.
Why Is a Registry for Wilson Disease So Important?
Even though treatments for Wilson disease have been available for more than 70 years, many important questions still don’t have clear answers. Doctors still face challenges in diagnosing the condition accurately, choosing the right treatment for each person, and knowing how well those treatments are working. That is why the Wilson Disease Registry) was created. It collects real-world data from patients around the world to help improve how Wilson disease is understood, diagnosed, and treated. Because Wilson disease is rare, gathering information in one place is critical—and can lead to better care for everyone affected.
By looking at the data, researchers and doctors can learn which tests are best for diagnosis, which treatments work well for different types of patients, and how to track whether those treatments are helping. The registry also sheds light on side effects and how the disease progresses, not just in the liver, but also the neurological and psychiatric aspects.
In short, the WDR is helping answer the big questions about Wilson disease—and is working to improve the quality of life for patients today and in the future.
What Is a Biorepository and Why Does It Matter for Wilson Disease?
Alongside the WDR, a biorepository was created to support current and future research. A biorepository is a secure place where biological samples—such as blood and DNA—are collected and stored from people with Wilson disease.
These samples help researchers study how to better diagnose the disease, monitor how it progresses, and discover which treatments work best. By donating samples, patients are directly contributing to studies that may lead to scientific breakthroughs for earlier disease detection, more personalized care, and better outcomes for everyone living with Wilson disease.
Your contribution could help change the future of Wilson disease treatment.
How to Get Involved
Adults and children diagnosed with Wilson disease are encouraged to participate in the WDR, regardless of where they are receiving their treatment. To get more information on the registry, participating sites and to enroll, please feel free to reach out to the team at the Yale Wilson Disease Center of Excellence.
(203) 376 6043

We would like to take this opportunity introduce Dr. Ayse Coskun, our new study lead coordinator at Yale, to the Wilson Disease Association membership. Ayse joined us in May 2019 and is working with each of our study sites to help initiate their active patient recruitment. We are pleased that recruitment has already started at Baylor College of Medicine in Houston, Texas where Dr. Sanjiv Harpavat has continued the work initiated by Dr. Tamir Miloh. Already three patients were recruited into the study at Baylor, and more will follow. Soon to begin enrollment this Summer are Florida Hospital, led by Dr. Regy Gonzalez, Seattle Childrens under the direction of Dr. Sihoun Hahn, and the Royal Surrey and Kings College Hospitals in the UK where Drs. Aftab Ala and Michelle Camarata are lead investigators.
